Search

Your search keyword '"Baum RP"' showing total 410 results
Start Over Author "Baum RP"
410 results on '"Baum RP"'

1. First proof-of-concept of theranostic instillation therapy for muscle invasive bladder cancer patients within the Bladder BRIDGister study group

Author

Barski, D, Wirtz, R, Kastner, L, Voß, PC, Friedersdorff, F, Otto, T, Waldner, M, Veltrup, E, Linden, F, Hake, R, Eidt, S, Roggisch, J, Rieger, C, Koch, S, Ecke, T, Heidenreich, A, Greifenstein, L, Baum, RP, Barski, D, Wirtz, R, Kastner, L, Voß, PC, Friedersdorff, F, Otto, T, Waldner, M, Veltrup, E, Linden, F, Hake, R, Eidt, S, Roggisch, J, Rieger, C, Koch, S, Ecke, T, Heidenreich, A, Greifenstein, L, and Baum, RP

Published
2024

2. 32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016.

Author

Langsteger, W, Rezaee, A, Loidl, W, Geinitz, HS, Fitz, F, Steinmair, M, Broinger, G, Pallwien-Prettner, L, Beheshti, M, Imamovic, L, Rendl, G, Hackl, D, Tsybrovsky, O, Emmanuel, K, Moinfar, F, Pirich, C, Bytyqi, A, Karanikas, G, Mayerhöfer, M, Koperek, O, Niederle, B, Hartenbach, M, Beyer, T, Herrmann, K, Czernin, J, Rausch, I, Rust, P, DiFranco, MD, Lassen, M, Stadlbauer, A, Mayerhöfer, ME, Hacker, M, Binzel, K, Magnussen, R, Wei, W, Knopp, MU, Flanigan, DC, Kaeding, C, Knopp, MV, Leisser, A, Nejabat, M, Kramer, G, Krainer, M, Haug, A, Lehnert, Wencke, Schmidt, Karl, Kimiaei, Sharok, Bronzel, Marcus, Kluge, Andreas, Wright, CL, Zhang, J, Wuthrick, Evan, Maniawski, Piotr, Blaickner, M, Rados, E, Huber, A, Dulovits, M, Kulkarni, H, Wiessalla, S, Schuchardt, C, Baum, RP, Knäusl, B, Georg, D, Bauer, M, Wulkersdorfer, B, Wadsak, W, Philippe, C, Haslacher, H, Zeitlinger, M, Langer, O, Feldmann, M, Karch, R, Koepp, MJ, Asselin, M-C, Pataraia, E, Zeilinger, M, Dumanic, M, Pichler, F, Pilz, J, Mitterhauser, M, Nics, L, and Steiner, B

Subjects
Medical Biochemistry and Metabolomics, Clinical Sciences, Oncology and Carcinogenesis
Abstract

Table of contentsA1 68Ga-PSMA PET/CT in staging and restaging of Prostate Cancer Patients: comparative study with 18F-Choline PET/CTW Langsteger, A Rezaee, W Loidl, HS Geinitz, F Fitz, M Steinmair, G Broinger, L Pallwien-Prettner, M BeheshtiA2 F18 Choline PET - CT: an accurate diagnostic tool for the detection of parathyroid adenoma?L Imamovic, M Beheshti, G Rendl, D Hackl, O Tsybrovsky, M Steinmair, K Emmanuel, F Moinfar, C Pirich, W LangstegerA3 [18F]Fluoro-DOPA-PET/CT in the primary diagnosis of medullary thyroid carcinomaA Bytyqi, G Karanikas, M Mayerhöfer, O Koperek, B Niederle, M HartenbachA4 Variations of clinical PET/MR operations: An international survey on the clinical utilization of PET/MRIT Beyer, K Herrmann, J CzerninA5 Standard Dixon-based attenuation correction in combined PET/MRI: Reproducibility and the possibility of Lean body mass estimationI Rausch, P Rust, MD DiFranco, M Lassen, A Stadlbauer, ME Mayerhöfer, M Hartenbach, M Hacker, T BeyerA6 High resolution digital FDG PET/MRI imaging for assessment of ACL graft viabilityK Binzel, R Magnussen, W Wei, MU Knopp, DC Flanigan, C Kaeding, MV KnoppA7 Using pre-existing hematotoxicity as predictor for severe side effects and number of treatment cycles of Xofigo therapyA Leisser, M Nejabat, M Hartenbach, G Kramer, M Krainer, M Hacker, A HaugA8 QDOSE - comprehensive software solution for internal dose assessmentWencke Lehnert, Karl Schmidt, Sharok Kimiaei, Marcus Bronzel, Andreas KlugeA9 Clinical impact of Time-of-Flight on next-generation digital PET imaging of Yttrium-90 radioactivity following liver radioembolizationCL Wright, K Binzel, J Zhang, Evan Wuthrick, Piotr Maniawski, MV KnoppA10 Snakes in patients! Lessons learned from programming active contours for automated organ segmentationM Blaickner, E Rados, A Huber, M Dulovits, H Kulkarni, S Wiessalla, C Schuchardt, RP Baum, B Knäusl, D GeorgA11 Influence of a genetic polymorphism on brain uptake of the dual ABCB1/ABCG2 substrate [11C]tariquidarM Bauer, B Wulkersdorfer, W Wadsak, C Philippe, H Haslacher, M Zeitlinger, O LangerA12 Outcome prediction of temporal lobe epilepsy surgery from P-glycoprotein activity. Pooled analysis of (R)-[11C]-verapamil PET data from two European centresM Bauer, M Feldmann, R Karch, W Wadsak, M Zeitlinger, MJ Koepp, M-C Asselin, E Pataraia, O LangerA13 In-vitro and in-vivo characterization of [18F]FE@SNAP and derivatives for the visualization of the melanin concentrating hormone receptor 1M Zeilinger, C Philippe, M Dumanic, F Pichler, J Pilz, M Hacker, W Wadsak, M MitterhauserA14 Reducing time in quality control leads to higher specific radioactivity of short-lived radiotracersL Nics, B Steiner, M Hacker, M Mitterhauser, W WadsakA15 In vitro 11C-erlotinib binding experiments in cancer cell lines with epidermal growth factor receptor mutationsA Traxl, Thomas Wanek, Kushtrim Kryeziu, Severin Mairinger, Johann Stanek, Walter Berger, Claudia Kuntner, Oliver LangerA16 7-[11C]methyl-6-bromopurine, a PET tracer to measure brain Mrp1 function: radiosynthesis and first PET evaluation in miceS Mairinger, T Wanek, A Traxl, M Krohn, J Stanek, T Filip, M Sauberer, C Kuntner, J Pahnke, O LangerA17 18F labeled azidoglucose derivatives as "click" agents for pretargeted PET imagingD Svatunek, C Denk, M Wilkovitsch, T Wanek, T Filip, C Kuntner-Hannes, J Fröhlich, H MikulaA18 Bioorthogonal tools for PET imaging: development of radiolabeled 1,2,4,5-TetrazinesC Denk, D Svatunek, T Wanek, S Mairinger, J Stanek, T Filip, J Fröhlich, H Mikula, C Kuntner-HannesA19 Preclinical evaluation of [18F]FE@SUPPY- a new PET-tracer for oncologyT Balber, J Singer, J Fazekas, C Rami-Mark, N Berroterán-Infante, E Jensen-Jarolim, W Wadsak, M Hacker, H Viernstein, M MitterhauserA20 Investigation of Small [18F]-Fluoroalkylazides for Rapid Radiolabeling and In Vivo Click ChemistryC Denk, D Svatunek, B Sohr, H Mikula, J Fröhlich, T Wanek, C Kuntner-Hannes, T FilipA21 Microfluidic 68Ga-radiolabeling of PSMA-HBED-CC using a flow-through reactorS Pfaff, C Philippe, M Mitterhauser, M Hartenbach, M Hacker, W WadsakA22 Influence of 24-nor-ursodeoxycholic acid on hepatic disposition of [18F]ciprofloxacin measured with positron emission tomographyT Wanek, E Halilbasic, M Visentin, S Mairinger, B Stieger, C Kuntner, M Trauner, O LangerA23 Automated 18F-flumazenil production using chemically resistant disposable cassettesP Lam, M Aistleitner, R Eichinger, C ArtnerA24 Similarities and differences in the synthesis and quality control of 177Lu-DOTA-TATE, 177Lu -HA-DOTA-TATE and 177Lu-DOTA-PSMA (PSMA-617)H Eidherr, C Vraka, A Haug, M Mitterhauser, L Nics, M Hartenbach, M Hacker, W WadsakA25 68Ga- and 177Lu-labelling of PSMA-617H Kvaternik, R Müller, D Hausberger, C Zink, RM AignerA26 Radiolabelling of liposomes with 67Ga and biodistribution studies after administration by an aerosol inhalation systemU Cossío, M Asensio, A Montes, S Akhtar, Y te Welscher, R van Nostrum, V Gómez-Vallejo, J LlopA27 Fully automated quantification of DaTscan SPECT: Integration of age and gender differencesF VandeVyver, T Barclay, N Lippens, M TrochA28 Lesion-to-background ratio in co-registered 18F-FET PET/MR imaging - is it a valuable tool to differentiate between low grade and high grade brain tumor?L Hehenwarter, B Egger, J Holzmannhofer, M Rodrigues-Radischat, C PirichA29 [11C]-methionine PET in gliomas - a retrospective data analysis of 166 patientsN Pötsch, I Rausch, D Wilhelm, M Weber, J Furtner, G Karanikas, A Wöhrer, M Mitterhauser, M Hacker, T Traub-WeidingerA30 18F-Fluorocholine versus 18F-Fluorodeoxyglucose for PET/CT imaging in patients with relapsed or progressive multiple myeloma: a pilot studyT Cassou-Mounat, S Balogova, V Nataf, M Calzada, V Huchet, K Kerrou, J-Y Devaux, M Mohty, L Garderet, J-N TalbotA31 Prognostic benefit of additional SPECT/CT in sentinel lymph node mapping of breast cancer patientsS Stanzel, G Pregartner, T Schwarz, V Bjelic-Radisic, B Liegl-Atzwanger, R AignerA32 Evaluation of diagnostic value of TOF-18F-FDG PET/CT in patients with suspected pancreatic cancerS Stanzel, F Quehenberger, RM AignerA33 New quantification method for diagnosis of primary hyperpatahyroidism lesions and differential diagnosis vs thyropid nodular disease in dynamic scintigraphyA Koljević Marković, Milica Janković, V Miler Jerković, M Paskaš, G Pupić, R Džodić, D PopovićA34 A rare case of diffuse pancreatic involvement in patient with merkel cell carcinoma detected by 18F-FDGMC Fornito, D FamiliariA35 TSH-stimulated 18F-FDG PET/CT in the diagnosis of recurrent/metastatic radioiodine-negative differentiated thyroid carcinomas in patients with various thyroglobuline levelsP Koranda, H Polzerová, I Metelková, L Henzlová, R Formánek, E Buriánková, M KamínekA36 Breast Dose from lactation following I131 treatmentWH Thomson, C LewisA37 A new concept for performing SeHCAT studies with the gamma cameraWH Thomson, J O'Brien, G James, A NotghiA38 Whole body F-18-FDG-PET and tuberculosis: sensitivity compared to x-ray-CTH Huber, I Stelzmüller, R Wunn, M Mandl, F Fellner, B Lamprecht, M GabrielA39 Emerging role 18F-FDG PET-CT in the diagnosis and follow-up of the infection in heartware ventricular assist system (HVAD)MC Fornito, G LeonardiA40 Validation of Poisson resampling softwareWH Thomson, J O'Brien, G JamesA41 Protection of PET nuclear medicine personnel: problems in satisfying dose limit requirementsJ Hudzietzová, J Sabol, M Fülöp.

Published
2016

3. Does the proteasome inhibitor bortezomib sensitize to DNA- damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo

Author

Briest, F, Koziolek, EJ, Albrecht, J, Schmidt, F, Bernsen, Monique, Haeck, Joost, Kuhl, AA, Sedding, D, Hartung, T, Exner, S, Welzel, M, Fischer, C, Grotzinger, C, Brenner, W, Baum, RP, Grabowski, P, Briest, F, Koziolek, EJ, Albrecht, J, Schmidt, F, Bernsen, Monique, Haeck, Joost, Kuhl, AA, Sedding, D, Hartung, T, Exner, S, Welzel, M, Fischer, C, Grotzinger, C, Brenner, W, Baum, RP, and Grabowski, P

Abstract

Background: Well-differentiated gastroenteropancreatic neuroendocrine neoplasms are rare tumors with a slow proliferation. They are virtually resistant to many DNA-damaging therapeutic approaches, such as chemo- and external beam therapy, which might be overcome by DNA damage inhibition induced by proteasome inhibitors such as bortezomib. Methods and results: In this study, we assessed several combined treatment modalities in vitro and in vivo. By cell-based functional analyses, in a 3D in ovo and an orthotopic mouse model, we demonstrated sensitizing effects of bortezomib combined with cisplatin, radiation and peptide receptor radionuclide therapy (PRRT). By gene expression profiling and western blot, we explored the underlying mechanisms, which resulted in an impaired DNA damage repair. Therapy-induced DNA damage triggered extrinsic proapoptotic signaling as well as the induction of cell cycle arrest, leading to a decreased vital tumor volume and altered tissue composition shown by magnetic resonance imaging and F-18-FDG-PET in vivo, however with no significant additional benefit related to PRRT alone. Conclusions: We demonstrated that bortezomib has short-term sensitizing effects when combined with DNA damaging therapy by interfering with DNA repair in vitro and in ovo. Nevertheless, due to high tumor heterogeneity after PRRT in long-term observations, we were not able to prove a therapeutic advantage of bortezomib-combined PRRT in an in vivo mouse model.

Published
2021

4. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

Author

Strosberg, J, Kunz, PL, Hendifar, A, Yao, J, Bushnell, D, Kulke, MH, Baum, RP, Caplin, M, Ruszniewski, P, Delpassand, E, Hobday, T, Verslype, C, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Paganelli, G, Severi, S, Morse, M, Metz, DC, Ansquer, C, Courbon, F, Al-Nahhas, A, Baudin, E, Giammarile, F, Taïeb, D, Mittra, E, Wolin, E, O’Dorisio, TM, Lebtahi, R, Deroose, CM, Grana, CM, Bodei, L, Öberg, K, Polack, BD, He, B, Mariani, MF, Gericke, G, Santoro, P, Erion, JL, Ravasi, L, Krenning, Eric, Strosberg, J, Kunz, PL, Hendifar, A, Yao, J, Bushnell, D, Kulke, MH, Baum, RP, Caplin, M, Ruszniewski, P, Delpassand, E, Hobday, T, Verslype, C, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Paganelli, G, Severi, S, Morse, M, Metz, DC, Ansquer, C, Courbon, F, Al-Nahhas, A, Baudin, E, Giammarile, F, Taïeb, D, Mittra, E, Wolin, E, O’Dorisio, TM, Lebtahi, R, Deroose, CM, Grana, CM, Bodei, L, Öberg, K, Polack, BD, He, B, Mariani, MF, Gericke, G, Santoro, P, Erion, JL, Ravasi, L, and Krenning, Eric

Published
2020

5. Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: First-in-Human Results, Biodistribution and Preliminary Dosimetry Estimations

Author

Baum, RP, additional, Smerling, C, additional, Schuchardt, C, additional, Singh, A, additional, Eismant, A, additional, Mishra, A, additional, Müller, D, additional, Zboralski, D, additional, Osterkamp, F, additional, Höhne, A, additional, Reineke, U, additional, and Kulkarni, HR, additional

Published
2020
Full Text
View/download PDF

6. The impact of prior therapies on overall survival in mCRPC patients receiving Lu-PSMA-617 therapy. A WARMTH retrospective multicenter trial

Author

Ahmadzadehfar, H, additional, Rahbar, K, additional, Baum, RP, additional, Gerke, C, additional, Kratochwil, C, additional, Ilhan, H, additional, Sathekge, M, additional, Kabasakal, L, additional, Garcia-Perez, F. O, additional, Kairemo, K, additional, Maharaj, M, additional, Paez, D, additional, and Virgolini, I, additional

Published
2020
Full Text
View/download PDF

7. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Author

Strosberg, J, El Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, Pl, Kulke, Mh, Jacene, H, Bushnell, D, O'Dorisio, Tm, Baum, Rp, Kulkarni, Hr, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, Jl, Ruszniewski, P, Kwekkeboom, D, Krenning, E, Ansquer, C, Baudin, E, Courbon, F, Giammarile, F, Taieb, D, Scheidhauer, K, Weber, M, Bodei, L, Brianzoni, E, DELLE FAVE, Gianfranco, Chiara Grana, M, Mariani, G, Rindi, G, Severi, S, Azevedo, I, Sundin, A, Al‐nahhas, A, Freemantle, N, Grossman, A, Manoharan, P, Anthony, L, Benson, Ab, Garbus, S, Kulke, M, Kvols, L, Metz, D, Morse, M, Schipper, M, Yao, J., and Radiology & Nuclear Medicine

Subjects
Male, medicine.medical_specialty, Octreotide, Antineoplastic Agents, Kaplan-Meier Estimate, Neuroendocrine tumors, Gastroenterology, Disease-Free Survival, Drug Administration Schedule, 030218 nuclear medicine & medical imaging, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Organometallic Compounds, medicine, Clinical endpoint, Humans, Infusions, Intravenous, Telotristat ethyl, Aged, Gastrointestinal Neoplasms, Tumors, DOTA-TATE, Intestins, business.industry, Nausea, General Medicine, receptor radionuclide therapy, radiolabeled somatostatin analog, carcinoid-syndrome, prognostic-factors, survival, prrt, lu-177-dota-octreotate, lu-177-octreotate, scintigraphy, octreotide, Middle Aged, medicine.disease, Surgery, Intestines, Clinical trial, Neuroendocrine Tumors, chemistry, Delayed-Action Preparations, 030220 oncology & carcinogenesis, Radionuclide therapy, Female, business, medicine.drug
Abstract

Background: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 ((177)Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. Methods: We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either (177)Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) ((177)Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here. Results: At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the (177)Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate was 18% in the (177)Lu-Dotatate group versus 3% in the control group (PConclusions: Treatment with (177)Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the (177)Lu-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239 ; EudraCT number 2011-005049-11 .).

Published
2017

8. Abstracts of the 33rd International Austrian Winter Symposium : Zell am See, Austria. 24-27 January 2018

Author

Binzel, K, Adelaja, A, Wright, CL, Scharre, D, Zhang, J, Knopp, MV, Teoh, EJ, Bottomley, D, Scarsbrook, A, Payne, H, Afaq, A, Bomanji, J, van As, N, Chua, S, Hoskin, P, Chambers, A, Cook, GJ, Warbey, VS, Chau, A, Ward, P, Miller, MP, Stevens, DJ, Wilson, L, Gleeson, FV, Scheidhauer, K, Seidl, C, Autenrieth, M, Bruchertseifer, F, Apostolidis, C, Kurtz, F, Horn, T, Pfob, C, Schwaiger, M, Gschwend, J, D'Alessandria, C, Morgenstern, A, Uprimny, C, Kroiss, A, Decristoforo, C, von Guggenberg, E, Nilica, B, Horninger, W, Virgolini, I, Rasul, S, Poetsch, N, Woehrer, A, Preusser, M, Mitterhauser, M, Wadsak, W, Widhalm, G, Mischkulnig, M, Hacker, M, Traub-Weidinger, T, Wuthrick, EJ, Miller, ED, Maniawski, P, Rep, S, Hocevar, M, Vaupotic, J, Zdesar, U, Zaletel, K, Lezaic, L, Mairinger, S, Filip, T, Sauberer, M, Flunkert, S, Wanek, T, Stanek, J, Okamura, N, Langer, O, Kuntner, C, Fornito, MC, Balzano, R, Di Martino, V, Cacciaguerra, S, Russo, G, Seifert, D, Kleinova, M, Cepa, A, Ralis, J, Hanc, P, Lebeda, O, Mosa, M, Vandenberghe, S, Mikhaylova, E, Borys, D, Viswanath, V, Stockhoff, M, Efthimiou, N, Caribe, P, Van Holen, R, Karp, JS, Haller, PM, Farhan, C, Piackova, E, Jäger, B, Knoll, P, Kiss, A, Podesser, BK, Wojta, J, Huber, K, Mirzaei, S, Traxl, A, Komposch, K, Glitzner, E, Sibilia, M, Russello, M, Sorko, S, Gallowitsch, HJ, Kohlfuerst, S, Matschnig, S, Rieser, M, Sorschag, M, Lind, P, Ležaič, L, Žibert, J, Frelih, N, Šuštar, S, Baum, RP, Langbein, T, Singh, A, Shahinfar, M, Schuchardt, C, Volk, GF, Kulkarni, HR, Di Martino, GV, Thomson, WH, Kudlacek, M, Karik, M, Rieger, H, Pokieser, W, Glaser, K, Petz, V, Tugendsam, C, Buchinger, W, Schmoll-Hauer, B, Schenk, IP, Rudolph, K, Krebs, M, Zettinig, G, Zoufal, V, Krohn, M, Pahnke, J, Weitzer, F, Pernthaler, B, Salamon, S, Aigner, R, Koranda, P, Henzlová, L, Kamínek, M, Váchalová, M, Bachleda, P, Summer, D, Garousi, J, Oroujeni, M, Mitran, B, Andersson, KG, Vorobyeva, A, Löfblom, JN, Orlova, A, Tolmachev, V, Kaeopookum, P, Orasch, T, Lechner, B, Petrik, M, Novy, Z, Rangger, C, and Haas, H

Published
2018

17. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group

Author

Miyahira, AK, Pienta, KJ, Morris, MJ, Bander, NH, Baum, RP, Fendler, WP, Goeckeler, W, Gorin, MA, Hennekes, H, Pomper, MG, Sartor, O, Tagawa, ST, Williams, S, Soule, HR, Miyahira, AK, Pienta, KJ, Morris, MJ, Bander, NH, Baum, RP, Fendler, WP, Goeckeler, W, Gorin, MA, Hennekes, H, Pomper, MG, Sartor, O, Tagawa, ST, Williams, S, and Soule, HR

Abstract

INTRODUCTION: The Prostate Cancer Foundation (PCF) convened a PSMA-Directed Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine, New York, NY. METHODS: The meeting was attended by 35 global investigators with expertise in prostate cancer biology, radionuclide therapy, molecular imaging, prostate-specific membrane antigen (PSMA)-targeted agents, drug development, and prostate cancer clinical trials. The goal of this meeting was to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the studies and clinical trials necessary for validating and optimizing the use of these agents. RESULTS: Several major topic areas were discussed including the overview of PSMA biology, lessons and applications of PSMA-targeted PET imaging, the nuances of designing PSMA-targeted radionuclide agents, clinical experiences with PSMA-targeted radionuclides, PCF-funded projects to accelerate PSMA-targeted radionuclide therapy, and barriers to the use of radionuclide treatments in widespread clinical practice. DISCUSSION: This article reviews the major topics discussed at the meeting with the goal of promoting research that will validate and optimize the use of PSMA-targeted radionuclide therapies for the treatment of advanced prostate cancer.

Published
2018

18. Recommendations for management of patients with neuroendocrine liver metastases

Author

Andrea, Frilling, Modlin, Irvin M., Mark, Kidd, Christopher, Russell, Stefan, Breitenstein, Riad, Salem, Dik, Kwekkeboom, Wan yee Lau, Catherine, Klersy, Valerie, Vilgrain, Brian, Davidson, Mark, Siegler, Martyn, Caplin, Enrico, Solcia, Richard, Schilsky, Adam, R, Akerstrom, G, Belghiti, J, Breitenstein, S, Clavien, Pa, Frilling, A, Gustafsson, B, Krenning, E, Modlin, Im, Norton, J, Öberg, K, Poston, G, Ruszniewski, P, Tait, P, Toogood, G, Russell, C, Bouvier, C, Jarecki, A, Klersy, C, Lau, Wj, Siegler, M, Rindi, G, Kidd, M, Vilgrain, V, Baum, Rp, Heaton, N, Garden, J, Fan, St, Van Gulik, T, Sipperstein, A, Kwekkeboom, D, Caplin, M, Lawrence, B, de Herder, W, Ito, T, Perren, A, Davidson, B, Klimstra, Ds, Kloppel, G, Scarpa, A, Meyer, T, Knuth, A, Chen, H, Van Cutsem, E, Pavel, Me, Kos Kudla, B, Conlon, K, Imamura, M, Kaltsas, G, Broering, D, Wiedenmann, B, Al Nahhas, A, Lodge, P, Cosimelli, M, Grazi, G, Tang, Lh, Salazar, R, Grossman, Ab, Dejong, C, Gores, G, Nagorney, Dm, Mazzaferro, V, Jensen, R, Lesurtel, M, Falconi, M, Hellmann, P, O'Toole, D, Olauson, M, Le Treut, Y, Burroughs, Ak, Valle, J, Kianmanesch, R, Sowa Staszczak, A, Milicevic, M, Lencioni, RICCARDO ANTONIO, Ramage, J, Sangro, B, Kennedy, A, Bester, L, Salem, R, Sharma, R, Parks, R, Bodei, L, Muller Brand, J, Kvols, L, Manas, D, Ramos, J, Wasan, H., Frilling, Andrea, Modlin Irvin, M., Kidd, Mark, Russell, Christopher, Breitenstein, Stefan, Salem, Riad, Kwekkeboom, Dik, Lau Wan, Yee, Klersy, Catherine, Vilgrain, Valerie, Davidson, Brian, Siegler, Mark, Caplin, Martyn, Solcia, Enrico, Schilsky, Richard, Falconi, Massimo, Andrea, Frilling, Modlin, Irvin M., Mark, Kidd, Christopher, Russell, Stefan, Breitenstein, Riad, Salem, Dik, Kwekkeboom, Wan-yee, Lau, Catherine, Klersy, Valerie, Vilgrain, Brian, Davidson, Mark, Siegler, Martyn, Caplin, Enrico, Solcia, Richard, Schilsky, for the Working Group on Neuroendocrine Liver Metastases,, Grazi, G., Radiology & Nuclear Medicine, and Internal Medicine

Subjects
medicine.medical_specialty, Biopsy, MEDLINE, clinical practice guidelines, hepatic metastases, prognostic factors, surgical management, Neuroendocrine tumors, surgical management, Systemic therapy, NO, medicine, Hepatectomy, Humans, hepatic metastases, Intensive care medicine, medicine.diagnostic_test, business.industry, Liver Neoplasms, prognostic factors, Interventional radiology, medicine.disease, Neoplastic Cells, Circulating, Neoadjuvant Therapy, Surgery, Clinical Practice, Neuroendocrine Tumors, Oncology, Genomic information, business, Working group, clinical practice guidelines
Abstract

Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research. © 2014 Elsevier Ltd.

Published
2014

21. Neoadjuvante Radionuklidtherapie in der Behandlung fortgeschrittener neuroendokriner Tumore

Author

Kaemmerer, D, Prasad, V, Baum, RP, and Hommann, M

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die meisten neuroendokrine Tumore werden in einem deutlich fortgeschrittenen Tumorstadium diagnostiziert. Die Chirurgie stellt die einzige kurative Behandlungsoption dar und wird häufig durch fortgeschrittenes Tumorwachstum und tumoröse Gefäßinfiltration limitiert. [for full text, please go to the a.m. URL], 131. Kongress der Deutschen Gesellschaft für Chirurgie

Published
2014
Full Text
View/download PDF

24. Radio guided surgery in neuroendocrine tumours with 68Ga-labeled somatostatin analogues – a pilot study

Author

Kämmerer, D, Prasad, V, Baum, RP, and Hommann, M

Subjects
ddc: 610, fungi, sense organs, 610 Medical sciences, Medicine
Abstract

Introduction: Radio-guided surgery (RGS) is an intraoperative localising technique for the detection of cancer tissue using tumour-specific radionuclides. The use of RGS has technically advanced and expanded in different kinds of tumour surgery. As of yet the experience with high energy gamma probe[for full text, please go to the a.m. URL], 128. Kongress der Deutschen Gesellschaft für Chirurgie

Published
2011
Full Text
View/download PDF

30. Role of PET/CT in the functional imaging of endocrine pancreatic tumors

Author

Rufini, Vittoria, Baum, Rp, Castaldi, Paola, Treglia, Giorgio, De Gaetano, Anna Maria, Carreras, C, Kaemmerer, D, Hommann, M, Hörsch, D, Bonomo, Lorenzo, Giordano, Alessandro, Rufini, Vittoria (ORCID:0000-0002-2052-8078), De Gaetano, Anna Maria (ORCID:0000-0002-7493-9462), Bonomo, Lorenzo (ORCID:0000-0001-5101-9367), Giordano, Alessandro (ORCID:0000-0002-6978-0880), Rufini, Vittoria, Baum, Rp, Castaldi, Paola, Treglia, Giorgio, De Gaetano, Anna Maria, Carreras, C, Kaemmerer, D, Hommann, M, Hörsch, D, Bonomo, Lorenzo, Giordano, Alessandro, Rufini, Vittoria (ORCID:0000-0002-2052-8078), De Gaetano, Anna Maria (ORCID:0000-0002-7493-9462), Bonomo, Lorenzo (ORCID:0000-0001-5101-9367), and Giordano, Alessandro (ORCID:0000-0002-6978-0880)

Abstract

Endocrine pancreatic tumors (EPTs) are a heterogeneous group of neoplasms with variable clinical and biological features and prognosis, ranging from very slow-growing tumors to highly aggressive and very malignant ones. As other neuroendocrine tumors, EPTs are characterized by the presence of neuroamine uptake mechanisms and/or peptide receptors at the cell membrane and these features constitute the basis of the clinical use of specific radiolabeled ligands, both for imaging and therapy. The more widespread use of hybrid machines, i.e., positron emission tomography/computed tomography (PET/CT), allows to perform imaging with high resolution and high diagnostic accuracy especially for small lesions, and to correlate anatomic location with function. The recent WHO recommendations for classification and prognostic factors help the selection of tracers likely to show a positive image on PET; therefore, tracers exploiting specific metabolic patterns ((18)F-DOPA and (11)C-5-HTP) or specific receptor expression ((68)Ga-DOTA-peptides) are suited to well-differentiated tumors, while the use of (18)F-FDG is preferred for poorly-differentiated neoplasms with high proliferative activity and loss of neuroendocrine features. In differentiated EPTs, (11)C-5-HTP performs better than (18)F-DOPA even though its use is hampered by its complex production and limited availability and experience; (68)Ga-peptides are indicated for all type of gastroenteropancreatic (GEP) neuroendocrine tumors, regardless of their functional activity. In addition, (68)Ga-DOTA-peptides play a distinctive role in planning peptide receptor radionuclide therapy.

Published
2012

31. Imaging of neuroendocrine tumors.

Author

Rufini, Vittoria, Calcagni, Maria Lucia, Baum, Rp, Rufini, Vittoria (ORCID:0000-0002-2052-8078), Calcagni, Maria Lucia (ORCID:0000-0002-0805-8245), Rufini, Vittoria, Calcagni, Maria Lucia, Baum, Rp, Rufini, Vittoria (ORCID:0000-0002-2052-8078), and Calcagni, Maria Lucia (ORCID:0000-0002-0805-8245)

Abstract

Neuroendocrine tumors (NETs) are rare neoplasms, which are characterized by the presence of neuroamine uptake mechanisms and/or peptide receptors at the cell membrane and these features constitute the basis of the clinical use of specific radiolabeled ligands, both for imaging and therapy. Radiolabeled metaiodobenzylguanidine (MIBG) was the first radiopharmaceutical used to specifically depict and localize catecholamine-secreting tumors (pheochromocytomas, paragangliomas, and neuroblastomas) and is still regarded as a first-choice imaging technique for diagnosis and follow-up; in patients with malignant disease, MIBG scintigraphy is an essential step to select patients for (131)I-MIBG therapy. Scintigraphy with (111)In- or (99m)Tc-labeled somatostatin analogs has become the main imaging technique for NETs, particularly those expressing a high density of somatostatin receptors, such as gastroenteropancreatic tumors; this procedure is used routinely for localizing the primary tumor, evaluating disease extension, monitoring the effect of treatment and for selecting patients for radioreceptor therapy. Since the recent development of hybrid machines, it has been possible to obtain images that simultaneously hold both anatomic (computed tomography [CT]) and functional (single-photon emission computed tomography [SPECT] or positron emission tomography [PET]) information, with great impact on diagnostic accuracy. Significant improvements have been made during the past few years with the development of highly specific radiopharmaceuticals for PET studies that reflect the different metabolic pathways of NETs, such as glucose metabolism ((18)F-fluorodeoxyglucose), the uptake of hormone precursors ((11)C-5-hydroxytryptophan, (11)C- or (18)F-dihydroxyphenylalanine, (18)F-fluorodopamine), the expression of receptors ((68)Ga-labeled somatostatin analogs), as well as the synthesis, storage, and release of hormones ((11)C-hydroxyephedrine and others). Among these radiopharmaceutical

Published
2006

32. Peptidrezeptor-Radionuklid-Therapie bei Neuroendokrinen Tumoren in Deutschland: Erste Ergebnisse eines multizentrischen Krebsregisters

Author

Hörsch, D, primary, Ezziddin, S, additional, Haug, A, additional, Gratz, KF, additional, Dunkelmann, S, additional, Krause, BJ, additional, Schümichen, C, additional, Bengel, FM, additional, Knapp, WH, additional, Bartenstein, P, additional, Biersack, HJ, additional, Plöckinger, U, additional, and Baum, RP, additional

Published
2012
Full Text
View/download PDF

42. Korrelation von FDG PET und histologem Regressionsgrad nach neoadjuvanter Radiochemotherapie fortgeschrittener nichtkleinzelliger Bronchialkarzinome

Author

Schmuecking, M, primary, Baum, RP, additional, Junker, K, additional, Bonnet, R, additional, Presselt, N, additional, Treutler, D, additional, Leonhardi, J, additional, Niesen, A, additional, Schneider, CP, additional, Hoeffken, K, additional, Wendt, TG, additional, Schmidt, A, additional, and Müller, KM, additional

Published
2003
Full Text
View/download PDF

45. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology.

Author

Salavati A, Prasad V, Schneider CP, Herbst R, Baum RP, Salavati, Ali, Prasad, Vikas, Schneider, Claus-Peter, Herbst, Rudolf, and Baum, Richard Paul

Abstract

Few studies have been published on the safety and feasibility of synchronous use of peptide receptor radionuclide therapy (PRRNT), as source of internal radiation therapy, in combination with chemotherapy. In this study we reported a 53-year-old man with stage IV Merkel cell carcinoma (MCC), who underwent synchronous internal radiation therapy and chemotherapy. Based on presumable poor prognosis with chemotherapy only, functional similarities of MCC with other neuroendocrine tumors and available evidence of effectiveness and safety of synchronous use of external beam radiation therapy and chemotherapy in treatment of high-risk MCC patients, our interdisciplinary neuroendocrine tumor board recommended him to add PRRNT to his ongoing chemotherapy. He received 2 courses of (177)Lu-DOTATATE(1, 4, 7, 10-Tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-1-D-Phe1-Tyr3-Thr8-octreotide) in combination with ongoing 8 cycles of liposomal doxorubicin based on standard protocols. Response to therapy was evaluated by (18)F-FDG and (68)gallium-somatostatin-receptor PET/CT. There was an impressive improvement of the clinical symptoms. However, follow-up PET/CT studies showed mixed pattern of response. Synchronous use of PRRNT and radiosensitizing chemotherapy seems safe and feasible in high risk MCC patients, however, further prospective studies and clinical trials are warranted to provide reliable evidence of possible pitfalls and effectiveness of PRRNT and (68)Ga-somatostatin-receptor PET/CT in the management of MCC. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

47. Tumor Markers, Liver Function Tests and Symptoms in 115 Patients with Isolated Colorectal Liver Metastases

Author

Gerhard Oremek, M. Lorenz, R. Inglis, Baum Rp, Gustav Hör, Seiffert U, Reimann-Kirkowa M, and C. Hottenrott

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, Clinical Biochemistry, Combined use, Gastroenterology, Pathology and Forensic Medicine, Resection, Biliary disease, 03 medical and health sciences, 0302 clinical medicine, Preoperative staging, Liver Function Tests, Antigen, Antigens, Neoplasm, Internal medicine, Biomarkers, Tumor, medicine, Humans, Neoplasm Staging, medicine.diagnostic_test, Tumor size, business.industry, General surgery, Liver Neoplasms, Imaging Procedures, medicine.disease, Carcinoembryonic Antigen, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Colorectal Neoplasms, business, Liver function tests
Abstract

Development of the hybridoma technique has made the identification of several new tumor antigens possible. Although it was hoped that they would be more tumor-specific, none of these markers are found exclusively in tumor or in serum of tumor patients. Compared with carcinoembryionic antigen (CEA) and liver function tests, the roles of these markers (CA 19-9, CA 125, CA 15-3) were prospectively evaluated in 115 patients with colorectal liver metastases. Patients were classified according to tumor volume (T1 75%), and the extension of infiltration (solitary/multiple/diffuse; unilateral, bilateral). Patients with benign liver or biliary disease served as a control group (n=63). Overall sensitivity was 87% for *1 , 50% for *2 and 38% for *3 , with a significant correlation with tumor size. CEA serum levels were elevated in 88% of all patients. CA 19-9 was less sensitive: positive in 59%. Because of some complementary elevations, the combined use of CEA, CA 19-9 and CA 125 raised sensitivity to 94%. CA 19-9 and LDH could be useful for confirmation because of their higher specificity; however, the specificity of CEA rose to 93% on using a cut-off of 10 ng/ml instead of 3 ng/ml. The results indicate that CEA and CA 19-9 as well as liver function tests are helpful for preoperative staging in conjunction with imaging procedures before liver resection or regional chemotherapy.

Published
1989

48. Immunoscintigraphy and Immunotherapy 1988 Report of the 3rd IRIST Meeting, Frankfurt/Main, March 1988

Author

Perkins Ac and Baum Rp

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Clinical Biochemistry, Pathology and Forensic Medicine, Immunoscintigraphy, Mice, 03 medical and health sciences, 0302 clinical medicine, medicine, Animals, Humans, Medical physics, Radionuclide Imaging, business.industry, Antibodies, Monoclonal, Immunotherapy, Rats, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Immunology, Immunologic Techniques, business
Published
1988

50. Extraossäre Nuklidanreicherung im Rahmen der Skelettszintigraphie

Author

Baum Rp, Brandhorst I, Hör G, and Maul Fd

Subjects
medicine.medical_specialty, Endocrinology, medicine.diagnostic_test, Chemistry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Nuclide, Scintigraphy, Heparin Calcium
Published
1985

Catalog

Books, media, physical & digital resources
See catalog results